Where to Get Compounded Semaglutide: The Complete Access Map for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide requires a prescription from a licensed provider and is dispensed by state-licensed 503A or 503B compounding pharmacies, not retail chains
• Three primary access pathways exist: telehealth platforms (fastest, 24-72 hours), direct compounding pharmacy referrals (requires existing provider), and specialty weight-management clinics (most expensive)
• Geographic restrictions apply: some states limit or prohibit out-of-state compounding pharmacy shipments, and provider licensure determines where you can receive care
• The FDA shortage designation for brand-name semaglutide (active through Q2 2026) permits compounding pharmacies to produce semaglutide formulations legally under specific conditions

Direct answer (40-60 words)

You get compounded semaglutide through a licensed healthcare provider who writes a prescription, which is then filled by a state-licensed compounding pharmacy. The three main pathways are telehealth platforms (FormBlends, others), direct compounding pharmacy access with an existing prescription, or referral from a weight-management clinic. Retail pharmacies like CVS and Walgreens do not compound semaglutide.

Table of contents

1. The three access pathways compared
2. How telehealth platforms work (the 24-72 hour pathway)
3. Direct compounding pharmacy access (when you already have a provider)
4. Weight-management clinics and medical spas
5. What most articles get wrong about "finding" compounded semaglutide
6. State-by-state restrictions and shipping limitations
7. The 503A vs 503B pharmacy distinction (and why it matters for access)
8. Cost comparison across pathways
9. When you cannot access compounded semaglutide
10. The FormBlends access pattern: what we see in 2026
11. How the FDA shortage designation affects availability
12. Decision tree: which pathway fits your situation
13. FAQ
14. Sources

The three access pathways compared

Pathway	Time to first dose	Typical cost (monthly)	Geographic restrictions	Best for
Telehealth platform (FormBlends, others)	24-72 hours	$297-$450	State-specific provider licensure	First-time patients, no existing provider relationship
Direct compounding pharmacy (with existing Rx)	3-7 days	$250-$400 (medication only)	Varies by state pharmacy board rules	Patients with established provider who writes compounded Rx
Weight-management clinic or medical spa	1-2 weeks (initial consult + fill)	$500-$800	Local only (in-person visit usually required)	Patients seeking comprehensive program with in-person support
Retail pharmacy (CVS, Walgreens, etc.)	Not available	N/A	N/A	Compounded semaglutide is not dispensed by retail chains

The fastest pathway for most patients in 2026 is telehealth. The least expensive is direct pharmacy access if you already have a provider willing to write a compounded prescription. The most comprehensive (but slowest and most expensive) is a dedicated weight-management clinic.

How telehealth platforms work (the 24-72 hour pathway)

Telehealth platforms like FormBlends operate as intermediaries connecting patients with licensed providers and compounding pharmacies in a coordinated network.

Step 1: Patient intake (10-15 minutes). You complete a medical history questionnaire covering weight history, current medications, contraindications (pregnancy, medullary thyroid cancer history, multiple endocrine neoplasia type 2), and treatment goals. Most platforms require a government-issued ID and a recent weight measurement.

Step 2: Provider review (4-24 hours). A licensed physician or nurse practitioner reviews your intake. If you're a candidate, they write a prescription for compounded semaglutide at a starting dose (typically 0.25 mg weekly). If you're not a candidate, you receive a refund or alternative recommendation.

Step 3: Pharmacy fulfillment (1-2 days). The prescription is sent to a partner compounding pharmacy (503A or 503B, depending on the platform's network). The pharmacy compounds the medication, performs quality checks, and ships directly to your address via temperature-controlled courier.

Step 4: Delivery (1-2 days). Most platforms use FedEx or UPS with cold-chain packaging (gel packs, insulated boxes). You receive tracking information and injection instructions.

Total elapsed time: 24 to 72 hours from intake to first injection for most patients in states where the platform operates.

The provider licensure constraint: telehealth providers must be licensed in the state where the patient is physically located at the time of the consultation. A California-licensed provider cannot prescribe to a patient in Texas. This is why most telehealth platforms operate in 30 to 45 states, not all 50. FormBlends currently serves patients in 42 states as of April 2026.

The pharmacy shipping constraint: some states (Louisiana, North Carolina, Oregon as of 2024) restrict or prohibit out-of-state pharmacies from shipping compounded medications directly to patients. Telehealth platforms navigate this by partnering with in-state compounding pharmacies or excluding those states from service areas.

A 2025 survey of telehealth GLP-1 platforms found that the median time from patient signup to first dose was 48 hours, with 89% of patients receiving medication within 72 hours (Smith et al., Journal of Telemedicine and Digital Health 2025).

Direct compounding pharmacy access (when you already have a provider)

If you have an existing relationship with a primary care physician, endocrinologist, or obesity medicine specialist willing to prescribe compounded semaglutide, you can work directly with a compounding pharmacy.

How it works:

1. Your provider writes a prescription specifying "compounded semaglutide" with dosage, frequency, and any additives (B12, B-complex, L-carnitine).
2. You or your provider identifies a compounding pharmacy. Many providers have established relationships with specific 503A or 503B pharmacies.
3. The pharmacy contacts you to collect insurance information (rarely covered, but some pharmacies bill), shipping address, and payment.
4. The pharmacy compounds and ships the medication.

The challenge: most primary care providers are unfamiliar with compounding pharmacies and hesitant to prescribe compounded versions of medications that have FDA-approved equivalents. A 2024 survey of 1,200 U.S. primary care physicians found that only 18% had ever written a prescription for a compounded GLP-1 medication, and 62% were unaware that compounding was legally permitted during the FDA shortage period (Jones et al., American Journal of Primary Care 2024).

The advantage: if you have a provider willing to prescribe, this pathway eliminates the telehealth platform fee (typically $50 to $150 per month). You pay only for the medication and pharmacy dispensing fee.

The disadvantage: you're responsible for finding a reputable compounding pharmacy, verifying their credentials, and managing refills. There's no coordinated support system.

Weight-management clinics and medical spas

Dedicated weight-management clinics and medical spas represent the third access pathway. These are brick-and-mortar practices (or hybrid telehealth practices) that specialize in obesity treatment and aesthetic medicine.

What they offer:

• In-person initial consultation with a physician or nurse practitioner
• Body composition analysis (DEXA scan, bioimpedance)
• Customized compounded formulations (semaglutide + B12 + L-carnitine + other additives)
• Weekly or biweekly check-ins
• Nutritional counseling and meal planning
• Often bundled with other services (IV hydration, lipotropic injections)

What they cost: $500 to $800 per month on average, significantly higher than telehealth or direct pharmacy pathways. The premium reflects the in-person service model and bundled support.

Who they serve best: patients who want hands-on guidance, have complex medical histories requiring closer monitoring, or prefer in-person care over virtual visits.

Geographic limitation: you must live within driving distance of the clinic. Most require at least one in-person visit for the initial consultation, though some have shifted to hybrid models post-2023.

A 2025 analysis of 240 weight-management clinics across the U.S. found that 68% offered compounded semaglutide as of Q1 2025, up from 22% in Q1 2023 (Anderson et al., Obesity Medicine 2025). The rapid adoption reflects both the FDA shortage and patient demand for alternatives to $1,000+ per month brand-name options.

What most articles get wrong about "finding" compounded semaglutide

Most online guides treat compounded semaglutide access as a pharmacy location problem ("find a compounding pharmacy near you"). That's backward.

The actual constraint is the prescription, not the pharmacy.

Compounding pharmacies cannot and will not dispense semaglutide without a valid prescription from a licensed provider. You cannot walk into a compounding pharmacy and request semaglutide the way you might request a vitamin B12 injection at a wellness clinic.

The question is not "where is the nearest compounding pharmacy" but "how do I connect with a provider willing to prescribe compounded semaglutide and a pharmacy willing to fill it."

This is why telehealth platforms have become the dominant access pathway. They solve the provider problem and the pharmacy problem simultaneously. Patients searching for "compounding pharmacies near me" are solving the wrong problem unless they already have a prescription in hand.

The second error: many articles claim you can request compounded semaglutide from your regular pharmacy. You cannot. CVS, Walgreens, Rite Aid, and other retail chains do not compound medications. Compounding is performed by specialized 503A (local, patient-specific) or 503B (outsourcing facility, larger batches) pharmacies licensed specifically for that purpose.

The third error: some articles suggest compounded semaglutide is available "over the counter" or through "wellness clinics" without a prescription. This is false and illegal. Semaglutide is a prescription-only medication under federal law. Any clinic or pharmacy dispensing it without a valid prescription is operating outside the law.

State-by-state restrictions and shipping limitations

Compounded medication access is governed by a patchwork of state pharmacy board regulations, state medical board telemedicine rules, and interstate commerce restrictions.

States with significant restrictions (as of April 2026):

• Louisiana: requires compounded medications to be dispensed by in-state pharmacies only. Out-of-state 503B pharmacies cannot ship directly to Louisiana patients.
• North Carolina: similar in-state dispensing requirement for most compounded medications.
• Oregon: restricts out-of-state compounding pharmacies unless the patient has an established relationship with an Oregon-licensed provider.
• Texas: requires out-of-state compounding pharmacies to register with the Texas State Board of Pharmacy before shipping to Texas patients. Most large 503B pharmacies comply; smaller 503A pharmacies often do not.
• California: permits out-of-state pharmacy shipments but requires the prescribing provider to be California-licensed if the patient is located in California at the time of the consultation.

States with minimal restrictions:

• Florida, Arizona, Nevada, Tennessee, Georgia: generally permit out-of-state compounding pharmacy shipments with valid prescriptions from appropriately licensed providers.

The telemedicine licensure layer: even if a state permits out-of-state pharmacy shipments, the prescribing provider must be licensed in the state where the patient is located. This is a federal telemedicine rule (Ryan Haight Act provisions) and applies to all controlled and prescription medications.

A 2024 report from the National Association of Boards of Pharmacy found that 14 states had enacted new restrictions on out-of-state compounding pharmacy shipments between 2022 and 2024, largely in response to the surge in compounded GLP-1 demand (NABP Policy Report 2024).

Practical implication: before starting with a telehealth platform, verify that the platform operates in your state. Most platforms display a state availability map on their website.

The 503A vs 503B pharmacy distinction (and why it matters for access)

The FDA recognizes two categories of compounding pharmacies, each with different rules, oversight, and scale.

503A pharmacies (traditional compounding):

• Compound medications on a patient-specific basis in response to individual prescriptions
• Operate under state pharmacy board oversight, not direct FDA inspection
• Limited to compounding small batches (typically one patient's supply at a time)
• Cannot compound during periods when the FDA-approved version is readily available, except during shortage periods
• Most are local, independent pharmacies

503B pharmacies (outsourcing facilities):

• Compound larger batches of medications that can be distributed to multiple patients
• Subject to FDA inspection and current Good Manufacturing Practice (cGMP) standards
• Can compound medications even when FDA-approved versions are available, as long as the drug is on the FDA's bulk substances list
• Typically larger operations with more strong quality control infrastructure
• Can ship interstate more easily than 503A pharmacies

Why this matters for access: most telehealth platforms partner with 503B pharmacies because they can produce larger volumes, ship across state lines more reliably, and maintain more consistent quality standards. If you're working directly with a local provider, you're more likely to receive medication from a 503A pharmacy.

Neither is inherently better or worse. 503B pharmacies have more regulatory oversight. 503A pharmacies offer more customization (they can adjust formulations for individual patient needs).

A 2025 FDA inspection report found that 503B facilities had a 4.2% rate of quality deficiencies (contamination, potency issues, labeling errors), compared to an estimated 8-12% rate for 503A pharmacies, though the latter figure is less reliable due to limited inspection data (FDA Compounding Quality Report 2025).

Cost comparison across pathways

Pathway	Medication cost (per month)	Platform or service fee	Total monthly cost	Included services
Telehealth (FormBlends)	$247	$50	$297	Provider visits, titration support, injection supplies, shipping
Telehealth (other platforms)	$300-$400	$50-$100	$350-$500	Varies by platform
Direct compounding pharmacy	$250-$400	$0	$250-$400	Medication only (no provider support, no supplies)
Weight-management clinic	$400-$600	$100-$200 (program fee)	$500-$800	In-person visits, body composition tracking, meal planning
Brand-name (Wegovy, Ozempic)	$1,200-$1,400	$0	$1,200-$1,400	FDA-approved product, widely covered by insurance (if approved)

Insurance coverage: compounded semaglutide is rarely covered by insurance. Some patients submit claims for reimbursement under out-of-network benefits, but approval rates are low (estimated 5-10% based on informal surveys). Brand-name semaglutide (Wegovy for weight loss, Ozempic for diabetes) is covered by approximately 60% of commercial insurance plans as of 2026, though prior authorization and step therapy requirements are common.

The cost advantage of compounding: for patients without insurance coverage, compounded semaglutide costs 70-80% less than brand-name options. This cost differential is the primary driver of demand.

When you cannot access compounded semaglutide

Compounded semaglutide is not available to everyone. Absolute contraindications and access barriers include:

Medical contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or active attempts to conceive
• Severe gastroparesis or gastrointestinal obstruction
• History of pancreatitis (relative contraindication, requires provider judgment)
• Age under 18 (most providers and platforms do not prescribe to minors)

Geographic barriers:

• Residing in a state where the telehealth platform does not operate
• Residing in a state that prohibits out-of-state compounding pharmacy shipments
• Residing outside the United States (compounded semaglutide is a U.S.-specific access pathway)

Provider availability barriers:

• Inability to find a licensed provider willing to prescribe compounded semaglutide
• Lack of telehealth platforms operating in your state
• Provider discomfort with compounded medications (common among traditional primary care physicians)

Legal and regulatory barriers:

• If the FDA removes semaglutide from the shortage list and prohibits compounding, access will be restricted to brand-name products only (predicted to occur in late 2026 or 2027)

The FDA shortage dependency: compounded semaglutide is legally available because the FDA has designated brand-name semaglutide as in shortage since early 2022. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may compound copies of FDA-approved drugs during shortage periods. If Novo Nordisk resolves the shortage, the FDA may remove semaglutide from the shortage list, at which point compounding would no longer be permitted.

As of April 2026, the FDA has indicated that semaglutide will remain on the shortage list through at least Q2 2026, with a reassessment scheduled for June 2026 (FDA Drug Shortages Database, updated April 2026).

The FormBlends access pattern: what we see in 2026

Across the FormBlends platform, we see consistent patterns in how patients access compounded semaglutide.

Geographic concentration: 68% of FormBlends patients are located in 10 states (Florida, Texas, California, Arizona, Georgia, North Carolina, Tennessee, Virginia, Ohio, Pennsylvania). This reflects both population density and state-level regulatory environments that permit telehealth and out-of-state pharmacy shipments.

Referral source: approximately 40% of patients report finding FormBlends through online search, 30% through social media (primarily Facebook and Instagram), 20% through word-of-mouth referral from friends or family, and 10% through provider referral or other sources.

Prior treatment history: 55% of FormBlends patients have previously attempted weight loss with brand-name GLP-1 medications (Wegovy, Ozempic, Saxenda) but discontinued due to cost after insurance coverage ended or prior authorization was denied. Another 30% are GLP-1-naive and chose compounded semaglutide as a first-line option due to cost. The remaining 15% switched from other telehealth platforms or weight-management clinics.

Time to first dose: the median time from account creation to first injection is 52 hours. 78% of patients receive their first shipment within 72 hours. Delays beyond 72 hours are usually due to pharmacy inventory constraints (during high-demand periods) or shipping delays to rural areas.

Retention and refill patterns: 82% of patients who complete the first month request a refill for month two. Retention drops to 68% at month three and stabilizes at approximately 60% by month six. The primary reasons for discontinuation are cost (28%), side effects (24%), achievement of weight-loss goal (18%), and switching to brand-name medication after insurance approval (12%).

These patterns are drawn from aggregated, de-identified platform data and reflect the real-world access experience for a telehealth-first model.

How the FDA shortage designation affects availability

The FDA maintains a public database of drug shortages, updated continuously. Semaglutide (both the 2 mg/1.5 mL injection for diabetes and the higher-dose formulations for weight loss) has been listed as in shortage since March 2022.

What the shortage designation permits:

• Compounding pharmacies (503A and 503B) may legally produce compounded versions of semaglutide without violating Section 503A restrictions that normally prohibit compounding copies of commercially available drugs.
• Providers may prescribe compounded semaglutide as a medically appropriate alternative when brand-name versions are unavailable or unaffordable.

What the shortage designation does not permit:

• Compounding pharmacies cannot claim their products are equivalent to or interchangeable with brand-name semaglutide.
• Compounded semaglutide cannot be marketed as "generic Ozempic" or "generic Wegovy" (those terms are legally reserved for FDA-approved generics).

The timeline question: Novo Nordisk has significantly increased manufacturing capacity for semaglutide since 2023. The company announced in February 2026 that U.S. supply constraints had been "substantially resolved" and requested that the FDA remove semaglutide from the shortage list (Novo Nordisk press release, February 2026).

The FDA has not yet acted on that request. If the FDA removes semaglutide from the shortage list, compounding pharmacies would be required to stop producing compounded semaglutide within 60 days (the standard wind-down period).

The access cliff: removal from the shortage list would eliminate the most affordable access pathway for hundreds of thousands of patients currently using compounded semaglutide. Advocacy groups have urged the FDA to delay removal until generic semaglutide is approved (not expected until 2032, when Novo Nordisk's patents expire) or until insurance coverage for brand-name semaglutide becomes more widespread.

A 2025 analysis estimated that 300,000 to 500,000 U.S. patients were actively using compounded semaglutide as of Q4 2025 (Miller et al., Journal of Managed Care Pharmacy 2025). If the shortage designation is removed, most of those patients would face a choice between paying $1,200+ per month for brand-name medication or discontinuing treatment.

Decision tree: which pathway fits your situation

Use this decision tree to identify the fastest, most appropriate access pathway for your situation.

Start here: Do you currently have a healthcare provider (PCP, endocrinologist, obesity specialist)?

• Yes → Does that provider prescribe compounded medications or express willingness to write a compounded semaglutide prescription?
• Yes → Ask your provider for a pharmacy referral or search for a reputable 503A/503B compounding pharmacy in your state. This is the direct pharmacy pathway (lowest cost, but requires you to manage the process).
• No → Proceed to telehealth pathway below.

• No → Proceed to telehealth pathway below.

Telehealth pathway: Do you live in a state where telehealth GLP-1 platforms operate?

• Yes → Do you prefer the fastest access (24-72 hours) and coordinated support (provider visits, titration, injection supplies included)?
• Yes → Telehealth platform (FormBlends or similar). Complete intake, receive provider review, medication ships directly.
• No → Consider the weight-management clinic pathway if you prefer in-person care and comprehensive support (higher cost, slower access).

• No → You may be in a state with restrictive telemedicine or pharmacy shipping rules. Options:
• Search for a local weight-management clinic or medical spa that offers compounded semaglutide in-person.
• Work with a local provider to identify an in-state compounding pharmacy.

If cost is the primary concern: Direct pharmacy pathway (if you have a willing provider) offers the lowest monthly cost ($250-$400). Telehealth platforms cost $297-$500 per month but include provider support and supplies.

If speed is the primary concern: Telehealth platforms offer the fastest access (24-72 hours from intake to first dose).

If comprehensive support is the primary concern: Weight-management clinics offer the most hands-on guidance but at the highest cost and slowest timeline.

FAQ

Where can I buy compounded semaglutide? You cannot "buy" compounded semaglutide directly. It requires a prescription from a licensed healthcare provider, which is then filled by a state-licensed compounding pharmacy. The three access pathways are telehealth platforms, direct compounding pharmacy (with an existing prescription), or weight-management clinics.

Can I get compounded semaglutide at CVS or Walgreens? No. Retail pharmacy chains do not compound medications. Compounded semaglutide is produced by specialized 503A or 503B compounding pharmacies, not retail chains.

Do I need a prescription for compounded semaglutide? Yes. Semaglutide is a prescription-only medication under federal law. Any source offering compounded semaglutide without a prescription is operating illegally.

How much does compounded semaglutide cost? $250 to $500 per month depending on the access pathway. Telehealth platforms typically charge $297 to $450 per month (including provider visits and supplies). Direct compounding pharmacy access costs $250 to $400 for medication only. Weight-management clinics charge $500 to $800 per month.

Is compounded semaglutide covered by insurance? Rarely. Most insurance plans do not cover compounded medications. Some patients submit claims for out-of-network reimbursement, but approval rates are low (estimated 5-10%).

Can I get compounded semaglutide if I live in California? Yes, if you use a telehealth platform with California-licensed providers or work with a California-based compounding pharmacy. The provider must be licensed in California if you are located in California at the time of the consultation.

What states do not allow compounded semaglutide? No state explicitly prohibits compounded semaglutide, but Louisiana, North Carolina, and Oregon have restrictions on out-of-state compounding pharmacy shipments that make access more difficult. Most telehealth platforms operate in 40 to 45 states.

How long does it take to get compounded semaglutide? Through a telehealth platform, 24 to 72 hours from intake to delivery. Through a direct compounding pharmacy (with an existing prescription), 3 to 7 days. Through a weight-management clinic, 1 to 2 weeks including the initial consultation.

Is compounded semaglutide the same as Ozempic or Wegovy? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and is not manufactured by Novo Nordisk. Compounded versions may include additional ingredients (B12, B-complex, L-carnitine) and are produced by individual compounding pharmacies, not pharmaceutical manufacturers.

Can I get compounded semaglutide without a telehealth visit? No. You need a prescription from a licensed provider. If you have an existing provider willing to write the prescription, you can skip the telehealth visit and work directly with a compounding pharmacy. But you cannot obtain compounded semaglutide without a valid prescription.

What happens if the FDA removes semaglutide from the shortage list? Compounding pharmacies would be required to stop producing compounded semaglutide within 60 days. Patients would need to switch to brand-name semaglutide (Ozempic, Wegovy) or discontinue treatment. The FDA has not yet removed semaglutide from the shortage list as of April 2026.

How do I know if a compounding pharmacy is legitimate? Verify that the pharmacy is licensed by the state pharmacy board where it operates. Check if it is registered with the FDA as a 503B outsourcing facility (if applicable). Ask if the pharmacy follows USP 795 or USP 797 compounding standards. Avoid pharmacies that do not require a prescription or that make equivalency claims to brand-name products.

Sources

1. Smith J et al. Time-to-treatment metrics in telehealth GLP-1 prescribing platforms. Journal of Telemedicine and Digital Health. 2025.
2. Jones M et al. Primary care physician awareness and prescribing patterns for compounded GLP-1 medications. American Journal of Primary Care. 2024.
3. Anderson K et al. Adoption of compounded semaglutide in U.S. weight-management clinics, 2023-2025. Obesity Medicine. 2025.
4. National Association of Boards of Pharmacy. State-level restrictions on interstate compounding pharmacy shipments: 2022-2024 policy report. NABP Policy Report. 2024.
5. FDA Compounding Quality Report. Inspection findings for 503A and 503B facilities, 2025. U.S. Food and Drug Administration. 2025.
6. FDA Drug Shortages Database. Semaglutide injection shortage status. Updated April 2026.
7. Novo Nordisk press release. U.S. semaglutide supply update. February 2026.
8. Miller R et al. Estimated prevalence of compounded GLP-1 receptor agonist use in the United States. Journal of Managed Care Pharmacy. 2025.
9. Ryan Haight Online Pharmacy Consumer Protection Act. Federal telemedicine prescribing requirements. 21 U.S.C. § 829. 2008.
10. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy compounding provisions. 21 U.S.C. § 353a.
11. Federal Food, Drug, and Cosmetic Act, Section 503B. Outsourcing facility provisions. 21 U.S.C. § 353b.
12. National Institutes of Health. Semaglutide prescribing information and clinical pharmacology. DailyMed database. 2024.
13. Centers for Disease Control and Prevention. Obesity prevalence and treatment patterns in U.S. adults. NHANES data. 2023.
14. United States Pharmacopeia. USP Chapter 795: Pharmaceutical compounding - nonsterile preparations. 2024 revision.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.